Close Menu

NEW YORK – In spite of the company's recent acquisition of GenePOC in an effort to fortify its diagnostics business, Meridian Bioscience's CEO said on Tuesday that it could be more than a year before that business reverses its slide.

On Tuesday, the Cincinnati-based firm announced a 6 percent drop in revenues year-over-year for its fiscal third quarter, with a 9 percent decline in its diagnostics business, driven primarily by a 21 percent decline in molecular diagnostics.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Sponsored by

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.